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Health andWellness Survey (NHWS) in Brazil.. QOL was measured by the physical
component score (PCS) and mental component score (MCS) of the Short Form-12
(SF-12). Loss of work/productivity was measured by the validated Work Productiv-
ity and Activity Impairment instrument. Medical resource utilization was mea-
sured by health care provider, emergency room visits and hospitalization in the
past 6 months. RESULTS: Of the 12,000 respondents, 215 (1.6%) were identified as
AD patient’s caregivers where 63.7% were women. The age group with the highest
proportion of caregivers was 45-54yrs old (36.2%), and they are significantly older
than non-caregivers (44.7 vs. 40.8, p0.05). AD caregivers group reported more
specific co-morbidities (insomnia 33.8%, cardiac arrhythmia 20.7%), similar mean
scores of PCS (49.8 vs. 49.7) andMCS (47.3 vs. 46.9), similar percentage of emergency
roomvisits (21.5% vs. 21.8%), and similar percentage of hospitalization visits (9.9 vs.
9.8) over the past 6months compared to the group of not caregivers of AD patients.
Furthermore, caregivers of AD patients’ group reported 22.3% impairment in daily
activity compared to 22.1% in the group of not caregivers of AD patients.
CONCLUSIONS: From the Brazil NHWS results, AD caregivers suffer from impair-
ment in QOL, work/productivity loss and more specific co-morbidities. Findings
indicate there is still an unmet medical need in AD caregivers in Brazil.
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OBJECTIVES: The majority of currently approved disease-modifying therapies for
Multiple Sclerosis (MS) are injectables; however, there is no validated injection
satisfaction questionnaire for patients with MS. The Satisfaction with Injection
Experience (SIE) questionnaire was developed as a reliable and valid scale to eval-
uate this critical aspect of MS treatment satisfaction. METHODS: The medical lit-
erature was reviewed to determine the domains that were relevant to MS injection
satisfaction. Five domains were identified, along with the most commonly used
response options and recall period. A draft SIE questionnaire was evaluated in
cognitive debriefing interviews with MS patients. The final 5-item SIE question-
naire utilized a 2-week recall period, a 5-point Likert scale, and was scored as an
unweighted mean composite with higher scores representing greater satisfaction.
Preliminary psychometric analyses were conducted using baseline data from EN-
CORE, a multicenter clinical trial designed to investigate 2 formulations of glati-
ramer acetate (GA) for subcutaneous injection. Data were analyzed using item-
total Spearman correlations, Cronbach’s alpha, and principal components
analysis.RESULTS:Complete datawere available for 142MSpatientswhohad been
on the currentlymarketed 20mg formulation of GA utilizing the autoject 2 for glass
syringe for at least 90 days (mean 4.8 years; SD 3.6). The mean score on the SIE
questionnaire was 4.1 (SD  0.8; range 1.0 to 5.0). All item-total Spearman correla-
tions were greater than 0.30 (range 0.34 to 0.79) and the SIE questionnaire demon-
strated excellent overall internal reliability (Cronbach’s alpha 0.82). Based on the
eigenvalues and scree plot of the principal components analysis, a single compo-
nent was extracted, with 58.6% of total variation explained. CONCLUSIONS: The
5-item SIE questionnaire exhibited good psychometric properties, including evi-
dence of reliability and content validity. Furthermore, this sample of MS patients,
who were long-term users of GA, reported high levels of satisfaction with their
injection experience.
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OBJECTIVES: To assess in short-term changes in employment status in relapsing-
remittingmultiple sclerosis (RRMS) patients are treated with either oral, once daily
placebo, once daily Laquinimod 0.6mg or weekly intramuscular (IM) injections of
Interferon beta 1a. METHODS: Patients residing within the United States (n  xx)
with RRMS and Expanded Disability Status Scale (EDSS)  5.5 were randomly as-
signed to receive Laquinimod 0.6mg once daily, oral placebo once daily or Inter-
feron -1a 30mcg intramuscular injection weekly in the randomized, placebo con-
trolled BRAVO trial. U.S. patients completed the validated Work Productivity and
Activity Impairment Scale-General Health (WPAI-GH) at baseline and every three
months thereafter. At study completion, patient’s transitions from 1) unemploy-
ment to employment; 2) no transition in employment; and 3) transitions from
unemployment to employment were assessed using univariate statistics.
RESULTS: Sixty-two patients residing in the United States completed theWPAI-GH
with comparable study populations assigned to each of the three study arms. Sta-
tistically significant differences were observed across the three treatment arms
when consideration was given to changes in employment status (p  0.001). Sev-
enty-seven percent of patients treatedwith Avonex reported no change in employ-
ment status during the course of the study while 81% of patients in each of the
Laquinimod or placebo arm reported no change. Patients enrolled in the Avonex
group report the greatest transition from employment to unemployment (18%)
compared to Laquinimod (9%) and placebo (6%). CONCLUSIONS: Managed care
pharmacists consider multiple factors when making formulary decisions. While
safety and efficacy are the primary considerations, other factors that influence
patients and employers are frequently evaluated. While exploratory in nature,
variations in changes in employment status may occur in RRMS patients treated
with alternative diseasemodifying therapies. These findings, however, are prelim-
inary in nature and warrant future consideration through additional research.
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OBJECTIVES: Emerging data suggest that even mild or subclinical mobility loss
associated withmultiple sclerosis (MS) may adversely affect health-related quality
of life (HrQoL). We evaluated the impact and timing of mobility impairment on
HrQoL. METHODS: The North American Committee on Multiple Sclerosis (NAR-
COMS) registry was used to conduct a cross-sectional study of participants who
completed the biannual update and supplemental Spring 2010 surveys. The NAR-
COMS Performance Scale for mobility was used to grade severity of mobility im-
pairment. HrQoL assessments included the Short Form(SF)-12, physical andmental
subscales (PCS and MCS), the EuroQoL (EQ)-5D, EQ-Visual Analog Scale (VAS), and
SF-6D. RESULTS: A total of 3483 registrants completed both surveys. Compared
with those rating themselves as “normal” (n628) on the mobility performance
scale, participants describing their disability as “minimal” (n566), “mild” (n535),
“occasional support usage” (n535), “frequent cane usage” (n527), “severe”
(n543), and “total” (n105) each reported poorer HrQoL scores on the PCS and
MCS (PCS range: 53.6-30.5, MCS range: 46.8-40.3; p0.001 for all). The largest rela-
tive decrement in PCS andMCS came at the transition from “normal” to “minimal”
(PCS: 15.1%, MCS: 6.2%) and “minimal” to “mild” mobility impairment (PCS: 15.4%,
MCS: 5.9%), with the detrimental effect of poorer mobility more profound on the
PCS, and little effect on the MCS after the earlier stages of mobility impairment.
Poorer health utility was also reported in participants in impairedmobility catego-
ries compared to “normal” when examined using each of the utility measures
(EQ-5D range: 0.89-0.53, EQ-VAS range: 0.83-0.55, SF-6D range: 0.78-0.58; p0.001
for all). The largest decrements in utility came at the transition from “normal” to
“minimal” (9.6%-10.3%) and “minimal” to “mild” mobility impairment (an addi-
tional 8.6%-10.7%). CONCLUSIONS: These data suggest that mobility impairment
may negatively affect HrQoL, with the most profound decrements occurring at
earlier stages of mobility loss.
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OBJECTIVES: To evaluate associations between changes in health status over time
and health-related quality of life (HRQOL) using the Cystic Fibrosis Questionnaire-
Revised (CFQ-R), a disease-specific patient-reported outcome (PRO) measure of
HRQOL. METHODS: Using the Epidemiologic Study of Cystic Fibrosis (ESCF) data,
we identified participants who had completed age-appropriate CFQ-R assessments
on 2 occasions separated by 9 to 15months.We developedmultivariable regression
models to test whether associations existed between 1) changes in respiratory
signs/symptoms and changes in the respiratory health domains of the CFQ-R; 2)
changes in nutritional health status and changes in the nutritional health domains
of the CFQ-R; and 3) changes in treatment complexity and changes in the Treat-
ment Burden scale of the CFQ-R. RESULTS:Weanalyzed 1947 pairs of assessments:
337 child (8.9, range 6-13 years), 581 parent (mean age of child 8.8, range 6-13 years),
398 adolescent (mean age 15.3, range 14-17 years), and 631 adult (mean age 26.9,
range 18-73 years). On average, we found little change in both health status indi-
cators and CFQ-R domain scores over 1 year. Significant associations over time,
however, were found with declining weight and worsening scores on the CFQ-R
nutritional health domains, and increases in treatment complexity and worsening
CFQ-R Treatment Burden scores for parent respondents. CONCLUSIONS: Health
status and HRQOL changes were small over a 1-year period in this CF population.
Changes in respiratory symptoms and weight, however, were associated with sig-
nificant changes on relevant CFQ-R scores, indicating that this PRO is sensitive to
changes in health status over time.
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OBJECTIVES: This post hoc analysis evaluated the use of rescue medication in the
acute treatment of migraine episodes reported during a randomized, placebo-con-
trolled, double-blind trial of MAP0004, an investigational, orally inhaled
dihydroergotamine. METHODS: Rescue medication use (RMU) was permitted in
this study if migraine symptomswere not relieved 2 hours after study drug admin-
istration. RMU in the MAP0004 and placebo treatment groups were adjusted for
baseline pain scores and compared according to demographic and baseline disease
characteristics (eg, age, gender, race, migraine history, baseline pain severity). The
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